CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
- 18 December 2012
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 20 (7), 2188-2196
- https://doi.org/10.1245/s10434-012-2809-1
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Pancreatic Cancer Surgery in the New MillenniumAnnals of Surgery, 2011
- Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapyBritish Journal of Cancer, 2010
- Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic AdenocarcinomaJournal of Gastrointestinal Surgery, 2009
- Resectable Pancreatic Cancer: Who Really Benefits From Resection?Annals of Surgical Oncology, 2009
- Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2008
- CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trialThe Lancet Oncology, 2008
- Carbohydrate antigen 19·9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancyBritish Journal of Surgery, 2007
- Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2006
- CA 19-9 Levels Predict Results of Staging Laparoscopy in Pancreatic CancerJournal of Gastrointestinal Surgery, 2005
- CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trialsBritish Journal of Cancer, 2005